Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis

BACKGROUND: Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide. The expiration of patents for these biologics has d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascef, Bruna O., Almeida, Matheus O., de Medeiros Ribeiro, Ana Cristina, Andrade, Danieli C. O., de Oliveira Júnior, Haliton A., Pereira, Tiago V., de Soárez, Patrícia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286602/
https://www.ncbi.nlm.nih.gov/pubmed/34274019
http://dx.doi.org/10.1186/s13643-021-01754-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286602/
https://www.ncbi.nlm.nih.gov/pubmed/34274019
http://dx.doi.org/10.1186/s13643-021-01754-x

Ejemplares similares